一种新的癌症治疗方法在肉瘤中显示出强大的效果，肿瘤显着缩小且副作用很少，促使进一步的试验。 A new cancer treatment showed strong results in sarcoma, with significant tumor shrinkage and few side effects, prompting further trials.

软组织肉瘤中联合使用eftilagimod alfa与放射治疗和KEYTRUDA的II期试验达到主要终点,显示瘤化/纤维化中位数为51. 5%,比历史对照组高出3倍,表明改善结果的潜力. A Phase II trial of eftilagimod alfa combined with radiotherapy and KEYTRUDA in soft tissue sarcoma met its primary endpoint, showing a median 51.5% tumor hyalinization/fibrosis—over three times higher than historical controls—signaling potential for improved outcomes. 治疗效果良好,几乎没有严重的副作用。 The treatment was well-tolerated, with minimal severe side effects. 在2025年ESMO大会上提出的结果支持进一步发展肉瘤和其他癌症,包括NSCLC和头癌,efti已获得FDA快速通道指标. Results, presented at the 2025 ESMO Congress, support further development in sarcoma and other cancers, including NSCLC and head and neck cancer, where efti has received FDA Fast Track designation. 在NSCLC的第三阶段试验已登记了170多名病人。 A Phase III trial in NSCLC has enrolled over 170 patients.